Compare ESRT & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESRT | NVCT |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 826.6M | 672.1M |
| IPO Year | 2012 | 2021 |
| Metric | ESRT | NVCT |
|---|---|---|
| Price | $5.42 | $19.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.50 | ★ $35.40 |
| AVG Volume (30 Days) | ★ 3.4M | 186.8K |
| Earning Date | 11-02-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $768,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.05 | N/A |
| 52 Week Low | $3.93 | $5.77 |
| 52 Week High | $7.13 | $29.28 |
| Indicator | ESRT | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 69.58 | 44.66 |
| Support Level | $5.25 | $17.73 |
| Resistance Level | $5.85 | $22.49 |
| Average True Range (ATR) | 0.15 | 1.45 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 82.91 | 36.82 |
Empire State Realty Trust Inc is a real estate investment trust (REIT) that owns and operates office, retail, and multifamily properties located in New York City, prominently in Manhattan. Its portfolio includes office and retail space as well as residential units. The company's objective is to maximize cash flow and total returns to its shareholders and to increase the value of the properties. Its reportable segments consist of a real estate segment and an Observatory segment. The majority of revenue is derived from the Real Estate segment, which includes all activities related to the ownership, management, operation, acquisition, redevelopment, repositioning and disposition of its traditional real estate assets.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.